Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton
October 19 2021 - 7:55AM
Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a
global leader in the development and delivery of psychedelic
therapies, announced today the opening of their Seattle clinic,
their sixth in the United States, along with the recent opening of
a location in Fredericton, NB, and the imminent opening of a
location in Vancouver, BC. As the largest provider of
psychedelic-assisted therapies globally, Field Trip continues to
distinguish itself as a leader in the emerging psychedelic industry
with continued expansion and growing demand.
Mental health continues to be a national health
crisis as rates of anxiety, depression and PTSD keep climbing.
Since opening its first location in March 2020, Field Trip’s
ketamine-assisted therapy (KAP) protocols have generated rapid and
meaningful improvements for many Field Trip clients as measured by
depression and anxiety scales. Based on the data collected to date,
Field Trip clients have reported that their depression symptoms
improved significantly from “severe” to “mild” on average (with the
Mean PHQ9 score of respondents decreasing from 17 to 6), and among
respondents such benefits were sustained for 120 days or longer
from commencement of treatment. These results suggest that the
benefits of Field Trip’s KAP program may compare favorably to
ketamine infusions. Each Field Trip Health center is designed to
provide an oasis-like setting with elements of nature to give Field
Trip clients a space for healing, growth and transformation through
psychedelic therapies. The entire experience is supported by Field
Trip’s digital technology and tools that guide people through the
process from before treatment is approved until after their
treatment program is complete, and beyond.
Dr. Ryan Yermus, Field Trip Health’s Chief
Clinical Officer, commented: “Since our first clinic opening in
Toronto, we have demonstrated the transformative power of our
psychedelic-assisted therapy protocols for people struggling with
their mental health. As we continue to grow into new markets, the
potential to positively change people’s lives is endless. We are
incredibly excited to deliver best-in-class psychedelic therapies
to the communities in Seattle, Vancouver and Fredericton.”
Hannan Fleiman, Field Trip’s President, added:
“Every center opening lays the groundwork for the development of
new psychedelic therapies. Not only are we healing the community
with the delivery of psychedelic medicine to patients, but we are
also ensuring the evolution of the psychedelic reawakening that is
happening in the field of mental health.”
The address for the Seattle clinic is 1200
Westlake Ave N Suite 600, Seattle, WA 98109 and people interested
in KAP in Seattle can get in touch by phone (1-888-519-6016) or
email (seattle@fieldtriphealth.com). The address for the
Fredericton clinic is 2398 Lincoln Rd Suite 3, Lincoln, NB E3B 7E6
and people interested in KAP in Fredericton can get in touch by
phone (1-833-222-0084) or by email
(fredericton@fieldtriphealth.com).
About Field Trip Health
Ltd.
Field Trip is the global leader in the
development and delivery of psychedelic therapies. With our Field
Trip Discovery division leading the development of the next
generation of psychedelic molecules and conducting advanced
research on plant-based psychedelics including psilocybin-producing
fungi and our Field Trip Health division building centers for
psychedelic therapies opening across North America and Europe along
with the digital and technological tools that will enable massive
scale, we help people from those in treatment to those seeking
accelerated personal growth, with a simple, evidence-based way to
heal and heighten engagement with the world.
Learn more at https://www.meetfieldtrip.com,
https://www.fieldtriphealth.com and
https://www.fieldtriphealth.nl.
Follow us on Twitter and Instagram:
@fieldtriphealth
To receive company updates about Field Trip and
to be added to the email distribution list please sign up here.
For further information, contact Ronan Levy,
Executive Chairman and a Director at Field Trip, at 1 (833)
833-1967.
Cautionary Note Regarding
Forward-Looking Information.
This release includes forward-looking
information (within the meaning of Canadian securities laws and
within the meaning of the United States Private Securities
Litigation Reform Act of 1995) regarding Field Trip and its
business. Often but not always, forward-looking information can be
identified by the use of words such as "expect", "intends",
"anticipated", "believes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would" or "will" be
taken, occur or be achieved. Such statements are based on the
current expectations and views of future events of the management
of Field Trip, and are based on assumptions and subject to risks
and uncertainties. Although the management of Field Trip believes
that the assumptions underlying these statements are reasonable,
they may prove to be incorrect. The forward-looking events and
circumstances discussed in this release may not occur and could
differ materially as a result of known and unknown risk factors and
uncertainties affecting the companies, including patient uptake for
ketamine assisted psychotherapy in existing and new clinic
locations, interest in the ketamine assisted psychotherapy training
program, interest in the KAP Co-Op Program, uptake of the KAP Co-Op
Program by therapists and patients, the timing and results of its
research and development programs, approval of phase 1 human
trials, if any, the risk that future clinical studies may not
proceed as expected or may produce unfavorable results, the opening
of additional clinics, the COVID-19 epidemic, the medical clinic
industry, market conditions, economic factors, management's ability
to manage and to operate the business and the equity markets
generally. Although Field Trip has attempted to identify important
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
statements, there may be other factors that cause actions, events
or results to differ from those anticipated, estimated or intended.
Accordingly, readers should not place undue reliance on any
forward-looking statements or information. No forward-looking
statement can be guaranteed. Except as required by applicable
securities laws, forward-looking statements speak only as of the
date on which they are made and Field Trip does not undertake any
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities.
Neither the Toronto Stock Exchange, nor its
Regulation Services Provider, have approved the contents of this
release or accept responsibility for the adequacy or accuracy of
this release.
Media contacts:
Rachel MoskowitzAutumn
Communications202-276-7881press@fieldtriphealth.com
Nick Opich / McKenna MillerKCSA Strategic
Communications212-896-1206 /
347-487-619press@fieldtriphealth.com
Investor contacts:
Elizabeth BarkerKCSA Strategic
Communications212-896-1203ebarker@kcsa.comSOURCE Field Trip Health
Ltd.
Field Trip Health (TSX:FTRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Field Trip Health (TSX:FTRP)
Historical Stock Chart
From Jul 2023 to Jul 2024